Regeneron Income Statement Research

REGN Stock

USD 957.00 19.39 2.07%

Most accounts from Regeneron Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Regeneron Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Regeneron Pharmaceuticals Valuation and Regeneron Pharmaceuticals Correlation analysis.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

At this time, Regeneron Pharmaceuticals' EBIT is very stable compared to the past year. As of the 6th of May 2024, EBITDA is likely to grow to about 4.2 B, while Income Tax Expense is likely to drop about 169.5 M.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.At this time, Regeneron Pharmaceuticals' EBIT is very stable compared to the past year. As of the 6th of May 2024, EBITDA is likely to grow to about 4.2 B, while Income Tax Expense is likely to drop about 169.5 M.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	4.7B	5.6B	7.1B	7.4B
Cost Of Revenue	2.4B	1.6B	883.7M	927.9M

Total Operating Expenses Cost Of Revenue

Regeneron Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Net Income	Income Before Tax	Total Other Income Expense Net	Income Tax Expense	Research Development	Selling General Administrative	Extraordinary Items	Net Income From Continuing Ops	Non Operating Income Net Other	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Non Recurring
Depreciation And Amortization		0.79	0.98	0.98	0.96	0.89	0.89	0.88	0.86	0.92	0.91	0.89	0.79	0.41	0.92	0.91	0.75	0.84	0.85	0.14	0.73	0.58	0.91	-0.55
Interest Expense	0.79		0.73	0.74	0.72	0.64	0.64	0.63	0.6	0.69	0.69	0.64	0.59	0.09	0.72	0.66	0.49	0.61	0.64	0.08	0.72	0.63	0.78	-0.61
Total Revenue	0.98	0.73		1.0	0.97	0.93	0.93	0.93	0.89	0.92	0.94	0.94	0.81	0.52	0.92	0.93	0.72	0.88	0.86	0.19	0.66	0.51	0.85	-0.51
Gross Profit	0.98	0.74	1.0		0.98	0.91	0.91	0.9	0.86	0.94	0.92	0.91	0.79	0.49	0.94	0.95	0.72	0.86	0.84	0.16	0.7	0.56	0.85	-0.55
Other Operating Expenses	0.96	0.72	0.97	0.98		0.83	0.83	0.82	0.79	0.98	0.84	0.83	0.73	0.43	0.98	0.98	0.71	0.77	0.79	0.02	0.74	0.6	0.85	-0.58
Operating Income	0.89	0.64	0.93	0.91	0.83		1.0	1.0	0.97	0.72	0.99	1.0	0.86	0.65	0.72	0.74	0.65	0.97	0.89	0.41	0.41	0.25	0.73	-0.28
Ebit	0.89	0.64	0.93	0.91	0.83	1.0		1.0	0.97	0.72	0.99	1.0	0.86	0.65	0.72	0.74	0.65	0.97	0.89	0.41	0.41	0.25	0.73	-0.28
Ebitda	0.88	0.63	0.93	0.9	0.82	1.0	1.0		0.98	0.71	0.99	1.0	0.87	0.66	0.71	0.73	0.65	0.98	0.89	0.4	0.38	0.22	0.72	-0.24
Cost Of Revenue	0.86	0.6	0.89	0.86	0.79	0.97	0.97	0.98		0.66	0.96	0.98	0.89	0.65	0.67	0.68	0.65	0.97	0.91	0.4	0.32	0.14	0.72	-0.15
Total Operating Expenses	0.92	0.69	0.92	0.94	0.98	0.72	0.72	0.71	0.66		0.74	0.72	0.63	0.33	1.0	1.0	0.67	0.65	0.69	-0.09	0.81	0.68	0.82	-0.66
Net Income	0.91	0.69	0.94	0.92	0.84	0.99	0.99	0.99	0.96	0.74		0.99	0.89	0.54	0.74	0.76	0.72	0.98	0.92	0.33	0.46	0.29	0.77	-0.32
Income Before Tax	0.89	0.64	0.94	0.91	0.83	1.0	1.0	1.0	0.98	0.72	0.99		0.88	0.64	0.72	0.75	0.66	0.98	0.9	0.4	0.41	0.24	0.73	-0.28
Total Other Income Expense Net	0.79	0.59	0.81	0.79	0.73	0.86	0.86	0.87	0.89	0.63	0.89	0.88		0.45	0.64	0.63	0.73	0.88	0.99	0.26	0.37	0.15	0.68	-0.23
Income Tax Expense	0.41	0.09	0.52	0.49	0.43	0.65	0.65	0.66	0.65	0.33	0.54	0.64	0.45		0.32	0.36	0.07	0.59	0.45	0.63	-0.08	-0.18	0.23	0.15
Research Development	0.92	0.72	0.92	0.94	0.98	0.72	0.72	0.71	0.67	1.0	0.74	0.72	0.64	0.32		0.99	0.67	0.65	0.7	-0.1	0.81	0.68	0.83	-0.66
Selling General Administrative	0.91	0.66	0.93	0.95	0.98	0.74	0.74	0.73	0.68	1.0	0.76	0.75	0.63	0.36	0.99		0.7	0.68	0.7	-0.08	0.77	0.64	0.8	-0.62
Extraordinary Items	0.75	0.49	0.72	0.72	0.71	0.65	0.65	0.65	0.65	0.67	0.72	0.66	0.73	0.07	0.67	0.7		0.67	0.77	-0.21	0.53	0.37	0.7	-0.38
Net Income From Continuing Ops	0.84	0.61	0.88	0.86	0.77	0.97	0.97	0.98	0.97	0.65	0.98	0.98	0.88	0.59	0.65	0.68	0.67		0.9	0.33	0.32	0.15	0.74	-0.13
Non Operating Income Net Other	0.85	0.64	0.86	0.84	0.79	0.89	0.89	0.89	0.91	0.69	0.92	0.9	0.99	0.45	0.7	0.7	0.77	0.9		0.23	0.42	0.21	0.73	-0.28
Tax Provision	0.14	0.08	0.19	0.16	0.02	0.41	0.41	0.4	0.4	-0.09	0.33	0.4	0.26	0.63	-0.1	-0.08	-0.21	0.33	0.23		-0.11	-0.13	0.04	0.05
Interest Income	0.73	0.72	0.66	0.7	0.74	0.41	0.41	0.38	0.32	0.81	0.46	0.41	0.37	-0.08	0.81	0.77	0.53	0.32	0.42	-0.11		0.97	0.79	-0.91
Net Interest Income	0.58	0.63	0.51	0.56	0.6	0.25	0.25	0.22	0.14	0.68	0.29	0.24	0.15	-0.18	0.68	0.64	0.37	0.15	0.21	-0.13	0.97		0.68	-0.92
Reconciled Depreciation	0.91	0.78	0.85	0.85	0.85	0.73	0.73	0.72	0.72	0.82	0.77	0.73	0.68	0.23	0.83	0.8	0.7	0.74	0.73	0.04	0.79	0.68		-0.52
Non Recurring	-0.55	-0.61	-0.51	-0.55	-0.58	-0.28	-0.28	-0.24	-0.15	-0.66	-0.32	-0.28	-0.23	0.15	-0.66	-0.62	-0.38	-0.13	-0.28	0.05	-0.91	-0.92	-0.52

Click cells to compare fundamentals

Regeneron Pharmaceuticals Account Relationship Matchups

Regeneron Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	30.2M	56.9M	57.3M	59.4M	73M	76.7M
Total Revenue	7.9B	8.5B	16.1B	12.2B	13.1B	13.8B
Gross Profit	7.1B	7.4B	13.6B	10.6B	12.2B	12.8B
Operating Income	2.2B	3.6B	8.9B	4.7B	4.0B	4.2B
Ebit	2.2B	3.6B	8.9B	4.7B	4.0B	4.2B
Ebitda	2.4B	3.9B	9.4B	5.2B	4.0B	4.2B
Cost Of Revenue	782.2M	1.1B	2.4B	1.6B	883.7M	927.9M
Net Income	2.1B	3.5B	8.1B	4.3B	4.0B	4.2B
Income Before Tax	2.4B	3.8B	9.3B	4.9B	4.2B	4.4B
Income Tax Expense	313.3M	297.2M	1.3B	520.4M	245.7M	169.5M
Research Development	3.0B	2.7B	2.9B	3.6B	4.4B	4.7B
Tax Provision	313.3M	297.2M	1.3B	520.4M	385.3M	584.1M
Interest Income	13.7M	88.1M	45.8M	160.1M	417.7M	438.6M
Net Interest Income	(30.2M)	(56.9M)	(57.3M)	100.7M	345.6M	362.9M

Regeneron Pharmaceuticals Investors Sentiment

The influence of Regeneron Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Regeneron. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.

Investor biases related to Regeneron Pharmaceuticals' public news can be used to forecast risks associated with an investment in Regeneron. The trend in average sentiment can be used to explain how an investor holding Regeneron can time the market purely based on public headlines and social activities around Regeneron Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.

Regeneron Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Regeneron Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Regeneron Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Implied Volatility

22.56

Regeneron Pharmaceuticals' implied volatility exposes the market's sentiment of Regeneron Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regeneron Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regeneron Pharmaceuticals stock will not fluctuate a lot when Regeneron Pharmaceuticals' options are near their expiration.

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regeneron Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regeneron Pharmaceuticals' short interest history, or implied volatility extrapolated from Regeneron Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

BILI	Bilibili
S	SentinelOne
BAC	Bank of America
GM	General Motors
GOOG	Alphabet Inc Class C

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:

How To Invest In Regeneron

Details

Is Regeneron Stock a good investment?

Details

What is Regeneron Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Regeneron Pharmaceuticals Valuation and Regeneron Pharmaceuticals Correlation analysis.

To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.

Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
	Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
	Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	FinTech Suite Use AI to screen and filter profitable investment opportunities

Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.13)

Earnings Share

33.88

Revenue Per Share

122.574

Quarterly Revenue Growth

(0.01)

Return On Assets

0.0774

The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Regeneron Income Statement Research

Regeneron Pharmaceuticals income statement Correlations

Regeneron Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Regeneron Pharmaceuticals income statement Accounts

Regeneron Pharmaceuticals Investors Sentiment

Regeneron Pharmaceuticals Implied Volatility

Currently Active Assets on Macroaxis

Complementary Tools for Regeneron Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 1.0	Total Revenue
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit
Income Before Tax	+ 1.0	Ebit

Non Recurring	- 0.92	Net Interest Income
Non Recurring	- 0.91	Interest Income
Non Recurring	- 0.66	Research Development
Non Recurring	- 0.66	Total Operating Expenses
Non Recurring	- 0.62	Selling General Administrative
Non Recurring	- 0.61	Interest Expense